Bamco Inc. NY Increases Stake in Arcellx, Inc.

Institutional investor boosts ownership of biotech company by 6.2% in Q3

Mar. 16, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an institutional investor, increased its stake in Arcellx, Inc. (NASDAQ:ACLX) by 6.2% during the third quarter, according to a recent SEC filing. The firm now owns 550,236 shares of the biotech company's stock, worth approximately $45.17 million.

Why it matters

Arcellx is a clinical-stage biopharmaceutical company focused on developing next-generation cell therapies for oncology and autoimmune diseases. Institutional investors like Bamco Inc. NY taking larger positions in the company signals confidence in its pipeline and future growth potential.

The details

According to the filing, Bamco Inc. NY acquired an additional 32,227 shares of Arcellx during the third quarter, bringing its total ownership to approximately 0.95% of the company's outstanding shares. The institutional investor now holds a $45.17 million stake in the biotech firm.

  • Bamco Inc. NY increased its Arcellx holdings during the 3rd quarter of 2026.

The players

Bamco Inc. NY

An institutional investor that manages assets and investments.

Arcellx, Inc.

A clinical-stage biopharmaceutical company focused on developing next-generation cell therapies.

Got photos? Submit your photos here. ›

The takeaway

Bamco Inc. NY's increased stake in Arcellx suggests the institutional investor sees strong growth potential in the biotech firm's pipeline of innovative cell therapies for cancer and autoimmune diseases.